The news: The FDA this week issued 30 warning letters to telehealth companies selling compounded GLP-1 weight loss drugs over false or misleading marketing claims. The action follows more than 50 similar letters sent in September, including to leading compounder Hims & Hers.

Many of the letters cite claims that the products contain the same active ingredients as FDA-approved drugs—in some cases naming Novo Nordisk’s Wegovy and Ozempic (semaglutide) and Eli Lilly’s Mounjaro and Zepbound (tirzepatide).

Why it matters: The latest enforcement blitz on telehealth is part of the FDA’s push on telehealth and pharma advertising across media platforms, with the growing stack of letters signaling more drug marketing scrutiny to come.

• In September, the Trump administration announced a crackdown on drug advertising on TV and online channels in September. The FDA followed with more than 100 cease-and-desist letters to pharma and telehealth companies.
• Last month, the agency said it plans to target compounded GLP-1s after Hims & Hers tried to sell a compounded version of Novo’s newly launched Wegovy pill.
• The FDA says it’s sent thousands of letters over the past six months to pharma and telehealth companies over misleading ads. Since 2014, the FDA has issued no more than 11 pharma promotion enforcement letters in any single year, per a RAPS’ analysis.

Implications for telehealth and pharma marketers: The FDA is targeting marketing claims rather than pulling products, making positioning—especially comparisons to branded GLP-1s—the main risk area. Telehealth companies should expect tighter oversight of websites, social media and ad copy, with less flexibility around how compounded drugs are described.

For pharma marketers, the broader push signals closer review of weight loss ads across TV, digital and social channels. Novo’s recent Apple-inspired Ozempic TV ad, for example, also got a warning letter last week. Campaigns that once felt edgy but acceptable may now require stronger vetting and more cautious creativity.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.